Veracyte, Inc. (NASDAQ:VCYT) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 20.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 174,463 shares of the biotechnology company's stock after buying an additional 30,059 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.23% of Veracyte worth $6,909,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Ieq Capital LLC bought a new stake in Veracyte during the 4th quarter valued at approximately $580,000. Barclays PLC grew its position in shares of Veracyte by 138.6% during the 3rd quarter. Barclays PLC now owns 146,402 shares of the biotechnology company's stock valued at $4,983,000 after acquiring an additional 85,033 shares during the period. Jennison Associates LLC boosted its holdings in Veracyte by 116.3% in the 4th quarter. Jennison Associates LLC now owns 833,754 shares of the biotechnology company's stock worth $33,017,000 after buying an additional 448,251 shares during the period. Bayesian Capital Management LP bought a new position in Veracyte in the 4th quarter worth $693,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Veracyte by 3.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 48,414 shares of the biotechnology company's stock valued at $1,918,000 after purchasing an additional 1,816 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms recently weighed in on VCYT. Stephens reissued an "overweight" rating and issued a $45.00 price objective on shares of Veracyte in a research report on Wednesday, March 26th. Wall Street Zen lowered shares of Veracyte from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Craig Hallum began coverage on shares of Veracyte in a research report on Thursday, March 20th. They issued a "buy" rating and a $45.00 price objective on the stock. Guggenheim reduced their price objective on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Finally, Needham & Company LLC reduced their price objective on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $40.90.

Veracyte Stock Down 1.1%

Shares of NASDAQ VCYT traded down $0.31 during midday trading on Thursday, reaching $26.98. 1,253,489 shares of the company's stock traded hands, compared to its average volume of 905,811. The stock's 50 day simple moving average is $29.67 and its 200-day simple moving average is $36.07. Veracyte, Inc. has a one year low of $19.73 and a one year high of $47.32. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -179.87 and a beta of 2.14.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.